2 documents found, page 1 of 1
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with mul...
Ferret-Sena, Véronique; Capela, Carlos; Macedo, Ana; Salgado, António Vasco; Derudas, Bruno; Staels, Bart; Sena, ArmandoFingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study w...
Natalizumab treatment modulates Peroxisome Proliferator-Activated Receptors exp...
Ferret-Sena, Véronique; Silva, Alexandra Maia e; Sena, Armando; Cavaleiro, Inês; Vale, José; Derudas, Bruno; Chinetti-Gbaguidi, Giulia; Staels, BartPeroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood i...